Media Coverage
Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.

J&J's ketamine-based drug drives sea change for new depression treatments

FDA clears J&J's esketamine in treatment-resistant depression, with restrictions as per REMS

Seeking a Cure: VistaGen Therapeutics' Potential Anti-Depression Drug

FDA approves Spravato nasal spray for depression

BioSpace's Global Biopharma Roundup: February 21
J&J nears FDA approval for landmark depression drug to replace ketamine treatments

Can We Treat Mood Disorders with Pharmacological Therapeutics?

Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression

VistaGen CEO notes broad market potential of ketamine-like AV-101